US equities |
META $624.67 ▼-0.93% TSLA $405.70 ▲+3.60% MU $930.59 ▲+2.98% NVDA $217.91 ▲+0.88% SPCX $150.76 ▲+2.63% AMD $559.20 ▲+5.25% SNDK $1,311.00 ▲+4.41% INTC $93.87 ▲+3.76%
FinancialContent

Exagen Inc. - Common Stock (NQ:XGN)

7.655 +0.185 (+2.48%)
Delayed Quote Updated: 12:30 PM EDT, Oct 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exagen Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Beyond The Numbers: 4 Analysts Discuss Exagen Stock ↗
 
Via Benzinga
News headline image
Exagen Inc. to Participate in Third Quarter Investor Conferences
From Exagen Inc.
Via GlobeNewswire
News headline image
What Analysts Are Saying About Exagen Stock ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Exagen Q2 Revenue Jumps 14 Percent ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Earnings Scheduled For July 29, 2025 ↗
 
Via Benzinga
News headline image
Earnings Scheduled For May 5, 2025 ↗
 
Via Benzinga
News headline image
Exagen Inc (NASDAQ:XGN) Surpasses Revenue Estimates in Q2 2025 Despite Wider Loss, Shares Rally in Pre-Market Trading ↗
Exagen Inc (XGN) beats Q2 2025 revenue estimates with $17.2M but posts wider loss. Stock jumps 6.77% pre-market as investors focus on growth potential. 
Via Chartmill
News headline image
Exagen Inc. Reports Strong Q2 2025 Results
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. Appoints Chas McKhann to Board of Directors
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. to Announce Second Quarter 2025 Financial Results on July 29, 2025
From Exagen Inc.
Via GlobeNewswire
News headline image
Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter’s Option to Purchase Additional Shares
From Exagen Inc.
Via GlobeNewswire
News headline image
Top movers in Thursday's pre-market session ↗
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
News headline image
Exagen Inc. Prices Public Offering of Common Stock
From Exagen Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Get insights into the top gainers and losers of Wednesday's after-hours session. ↗
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Exagen Inc. Announces Proposed Public Offering of Common Stock
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights
From Exagen Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For March 11, 2025 ↗
 
Via Benzinga
News headline image
Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. to Participate in Upcoming Investor Conferences
From Exagen Inc.
Via GlobeNewswire
News headline image
Tuesday's session: top gainers and losers ↗
Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements. 
Via Chartmill
News headline image
Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD
The milestone demonstrates AVISE CTD’s value and adoption within the rheumatologic community, clearly demonstrating superior laboratory testing for improved patient care 
From Exagen Inc.
Via GlobeNewswire
News headline image
Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform
Significant enhancements will equip clinicians with even more diagnostic clarity in the treatment of patients with autoimmune disease 
From Exagen Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >